Structure Other Stockholder Equity from 2010 to 2024
GPCR Stock | 34.20 0.44 1.30% |
Other Stockholder Equity | First Reported 2010-12-31 | Previous Quarter 659 M | Current Value 692 M | Quarterly Volatility 259.8 M |
Check Structure Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Structure main balance sheet or income statement drivers, such as Tax Provision of 247.8 K, Net Interest Income of 14.1 M or Depreciation And Amortization of 996.6 K, as well as many exotic indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 3.47. Structure financial statements analysis is a perfect complement when working with Structure Therapeutics Valuation or Volatility modules.
Structure | Other Stockholder Equity |
Latest Structure Therapeutics' Other Stockholder Equity Growth Pattern
Below is the plot of the Other Stockholder Equity of Structure Therapeutics American over the last few years. It is Structure Therapeutics' Other Stockholder Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Structure Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Other Stockholder Equity | 10 Years Trend |
|
Other Stockholder Equity |
Timeline |
Structure Other Stockholder Equity Regression Statistics
Arithmetic Mean | 38,790,477 | |
Geometric Mean | 40,890,230 | |
Coefficient Of Variation | 669.67 | |
Mean Deviation | 169,783,395 | |
Median | (58,000,570) | |
Standard Deviation | 259,766,974 | |
Sample Variance | 67478.9T | |
Range | 823M | |
R-Value | 0.58 | |
Mean Square Error | 48300.5T | |
R-Squared | 0.34 | |
Significance | 0.02 | |
Slope | 33,636,566 | |
Total Sum of Squares | 944704.3T |
Structure Other Stockholder Equity History
About Structure Therapeutics Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Structure Therapeutics income statement, its balance sheet, and the statement of cash flows. Structure Therapeutics investors use historical funamental indicators, such as Structure Therapeutics's Other Stockholder Equity, to determine how well the company is positioned to perform in the future. Although Structure Therapeutics investors may use each financial statement separately, they are all related. The changes in Structure Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Structure Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Structure Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Structure Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last Reported | Projected for Next Year | ||
Other Stockholder Equity | 659 M | 692 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out the analysis of Structure Therapeutics Correlation against competitors. Note that the Structure Therapeutics information on this page should be used as a complementary analysis to other Structure Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Complementary Tools for Structure Stock analysis
When running Structure Therapeutics' price analysis, check to measure Structure Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Structure Therapeutics is operating at the current time. Most of Structure Therapeutics' value examination focuses on studying past and present price action to predict the probability of Structure Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Structure Therapeutics' price. Additionally, you may evaluate how the addition of Structure Therapeutics to your portfolios can decrease your overall portfolio volatility.
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world |
Is Structure Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Structure Therapeutics. If investors know Structure will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Structure Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.25) | Return On Assets (0.22) | Return On Equity (0.33) |
The market value of Structure Therapeutics is measured differently than its book value, which is the value of Structure that is recorded on the company's balance sheet. Investors also form their own opinion of Structure Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Structure Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Structure Therapeutics' market value can be influenced by many factors that don't directly affect Structure Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Structure Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Structure Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Structure Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.